Perhaps most reassuring about semaglutide’s cardiovascular benefits is their durability over time. The protection against major adverse cardiac events persisted throughout the study’s follow ...

At just three months, before dose titration was over, participants on semaglutide had a noted decreased risk for stroke, heart attack, or cardiovascular death, with additional benefits at six months.

Despite this added complication, the study found that semaglutide still provided significant benefits to patients with heart failure. The data comes from the SELECT trial, a landmark study that ...

At just three months, before dose titration was over, participants on semaglutide had a noted decreased risk for stroke, heart attack, or cardiovascular death, with additional benefits at six months.

Semaglutide can help reduce the risk of heart attack and stroke for people with type 2 diabetes and heart disease. Research continues on whether that's related to weight loss.

In SELECT, semaglutide showed a 20% reduction in major adverse cardiovascular events (MACE) – including cardiovascular death, non-fatal heart attack, or non-fatal stroke – with the benefits ...

The anti-obesity medication semaglutide may help to prevent heart attacks and other major adverse cardiac events among overweight people who have cardiovascular disease, whether or not they also ...

New weight-loss drug Wegovy has major heart benefits, too. ... Semaglutide is part of a new class of drugs called GLP-1 receptor agonists developed to treat diabetes but is now also used to treat ...

However, the new Lancet study found semaglutide had similar benefits in people with heart failure: the drug was linked to a 28% reduction in major adverse cardiovascular events, and a 24% ...

Novo Nordisk’s , opens new tab diabetes medicine Rybelsus, an oral form of the GLP-1 drug semaglutide, provides similar cardiovascular benefits as the injectable forms of the drug, researchers ...

The heart risk difference between patients who received Wegovy, known chemically as semaglutide, and those on placebo began to appear almost immediately after starting treatment, researchers said.

Treatment was discontinued more often in the semaglutide group, primarily driven by gastrointestinal disorders (14.7% vs 9.0% in the heart failure groups; and 17.2% vs 7.9% in non-heart failure ...